Understand what your cancer tumor marker testing results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
What LDH actually measures
Lactate dehydrogenase is an enzyme that helps convert glucose into energy inside your cells. Think of it as part of your cellular power plant. Every tissue in your body contains LDH, but some areas have much higher concentrations.
Your heart, liver, kidneys, muscles, brain, and blood cells are particularly rich in LDH. When these tissues experience damage, stress, or rapid turnover, cells break open and dump their LDH contents into your bloodstream. Your blood test measures this spillover.
LDH isn't specific to one organ or condition. It's more like a smoke detector that alerts you to cellular damage somewhere in your body, but doesn't tell you exactly where the fire is burning. This makes LDH useful as a screening tool but requires additional testing to pinpoint the source.
The enzyme exists in five different forms (isoenzymes), each more common in specific tissues. Advanced testing can identify which isoenzyme is elevated, providing clues about whether the damage involves your heart, liver, muscles, or other areas.
Normal versus optimal LDH levels
Most labs set the normal range for LDH between 140-280 U/L, though some extend this to 300 U/L. These reference ranges represent the middle 95% of values from apparently healthy people, not necessarily optimal levels.
What's considered "high" depends on several factors. Age matters: children and teenagers often have higher baseline LDH due to rapid growth and development. Pregnancy can also elevate levels. Some people naturally run higher or lower within the normal range.
Your individual pattern provides more insight than population averages. If your LDH typically runs around 200 U/L and suddenly jumps to 350 U/L, that's more significant than someone whose baseline is consistently around 320 U/L.
Levels above 400 U/L generally warrant investigation, especially with symptoms. Extremely high levels (above 1,000 U/L) often indicate serious conditions like tissue death, certain cancers, or severe hemolysis (red blood cell destruction). Context and related biomarkers help determine urgency.
What high LDH levels can mean
Elevated LDH can signal various types of cellular damage. Heart attacks cause LDH to rise as heart muscle cells die, though other markers like troponin are more specific and faster. Liver damage from medications, alcohol, or disease releases LDH along with liver enzymes like ALT and AST.
Muscle damage from intense exercise, injury, or muscle diseases can spike LDH levels. Marathon runners or people who've had significant muscle trauma often show temporary elevations. Blood disorders like hemolytic anemia destroy red blood cells, releasing their high LDH content.
Certain cancers, particularly blood cancers like lymphoma and leukemia, can dramatically increase LDH. Solid tumors with rapid growth or cell death also elevate levels. This makes LDH useful in cancer monitoring, though it's not diagnostic by itself.
Infections, especially those causing significant tissue damage or inflammation, can raise LDH. Pneumonia, meningitis, and severe bacterial infections often show elevated levels alongside other inflammatory markers like C-reactive protein.
What low LDH levels can mean
Low LDH levels are less common and usually less concerning than high levels. Your body constantly produces LDH as part of normal cellular metabolism, so extremely low levels are rare unless something is interfering with cellular function.
Certain genetic conditions can affect LDH production, though these are uncommon. Some medications might temporarily lower levels. Severe nutritional deficiencies that impair cellular metabolism could theoretically reduce LDH, though other symptoms would be apparent first.
More often, "low" LDH simply reflects good cellular health with minimal ongoing damage or turnover. If you're healthy and your LDH sits at the lower end of the normal range, this generally indicates your tissues are functioning well without significant stress.
Lab error or sample handling issues occasionally produce falsely low results. If your LDH seems unusually low compared to previous tests, discussing a retest with your care team makes sense, especially if accompanied by unexplained symptoms.
How LDH is tested
LDH testing requires a simple blood draw, typically from a vein in your arm. No fasting is required, and you can take medications normally unless specifically instructed otherwise. The blood sample goes to a lab where automated analyzers measure enzyme activity.
Sample handling matters for accurate results. LDH is released when blood cells break down, so rough handling or delayed processing can artificially elevate levels. Hemolysis (breakdown of red blood cells) in the sample can significantly increase measured LDH even if your actual blood level is normal.
Results are usually available within 24-48 hours. If your care team suspects muscle damage, heart problems, or certain cancers, they might order LDH along with other specific markers to provide better context for interpretation.
Retesting frequency depends on your situation. For monitoring known conditions like cancer treatment response, testing might occur every few weeks. For general health screening, annual testing is often sufficient unless symptoms develop or other biomarkers suggest cellular damage.
What can change LDH
Physical factors significantly influence LDH levels. Intense exercise, especially activities involving muscle damage like weight lifting or long-distance running, can temporarily elevate LDH for 24-72 hours. Heat stroke or severe dehydration can also increase levels.
Medications affect LDH in various ways. Some chemotherapy drugs, antibiotics, and pain medications can cause tissue damage that raises LDH. Statins occasionally cause muscle damage that increases levels, though this is uncommon at standard doses.
Medical procedures involving tissue trauma can temporarily spike LDH. Surgery, biopsies, or even aggressive massage can release cellular contents. Blood transfusions might temporarily alter levels if the donated blood has different LDH concentrations.
Underlying health conditions create chronic LDH elevation. Liver disease, kidney problems, muscle disorders, blood diseases, and active cancers can keep levels consistently high. Treating the underlying condition typically normalizes LDH over time.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Connecting LDH to related biomarkers
LDH interpretation improves dramatically when viewed alongside related markers. Liver enzymes (ALT, AST, alkaline phosphatase) help determine if elevation comes from liver damage. If LDH and liver enzymes rise together, liver problems are likely.
Muscle-specific markers like creatine kinase (CK) clarify whether muscle damage is contributing to LDH elevation. High LDH with normal CK suggests non-muscle sources like liver, heart, or blood cells.
Inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) provide context about whether LDH elevation relates to infection, inflammation, or tissue damage. Complete blood counts can reveal blood disorders that might explain high LDH.
Heart-specific markers like troponin are much more sensitive for heart damage than LDH. If you have chest pain with high LDH but normal troponin, heart attack is less likely. Kidney function markers help determine if kidney damage is contributing to LDH changes.
Why testing LDH is worth it
LDH serves as an early warning system for cellular damage across multiple organ systems. While not specific to any single condition, it can flag problems before symptoms become obvious or other markers change.
For cancer monitoring, LDH provides valuable information about tumor activity and treatment response. Rising levels might indicate disease progression, while falling levels suggest treatment effectiveness. This makes regular monitoring worthwhile for people with known cancers.
The test's broad sensitivity makes it useful for general health screening. Unexplained fatigue, muscle weakness, or other vague symptoms might have underlying causes that LDH elevation could help identify when combined with other biomarkers.
Tracking LDH over time reveals patterns that single measurements miss. Gradually rising levels might indicate developing problems, while stable levels suggest good cellular health. This longitudinal view provides insights that symptom assessment alone cannot capture.
Understanding your LDH results
Knowing what is considered a high LDH level gives you a starting point, but interpreting your results requires seeing the complete picture. Your symptoms, other biomarkers, medical history, and trends over time all influence what your LDH level means for your health.
Superpower's comprehensive panels measure LDH alongside liver enzymes, inflammatory markers, and other indicators of cellular health. This integrated approach reveals patterns that isolated testing misses, giving you actionable insights rather than confusing numbers.
Ready to understand what your cellular health markers are telling you? Get your Superpower Blood Panel and see how LDH fits into your complete health picture.
Frequently Asked Questions
References
- Ali F, Ullah A, Amjad W, Kochar T, Annie FH, Farooq A (2018). A Case of Recurrent Thrombotic Microangiopathy Caused by Hypertensive Urgency. *Cureus*, *10*(8), e3235. https://doi.org/10.7759/cureus.3235
- Farhana A, Lappin SL (2023). *Biochemistry, lactate dehydrogenase*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557536/
- Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S (2015). Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. *Acta oncologica (Stockholm, Sweden)*, *54*(7), 961-70. https://doi.org/10.3109/0284186X.2015.1043026
- Petrelli F, Coinu A, Cabiddu M, Borgonovo K, Lonati V, Ghilardi M, Barni S (2015). Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients. *Medical oncology (Northwood, London, England)*, *32*(2), 456. https://doi.org/10.1007/s12032-014-0456-z
- Lippi G, Salvagno GL, Montagnana M, Brocco G, Guidi GC (2006). Influence of hemolysis on routine clinical chemistry testing. *Clinical chemistry and laboratory medicine*, *44*(3), 311-6. https://doi.org/10.1515/CCLM.2006.054
- Koukourakis MI, Giatromanolaki A, Sivridis E, Tumour and Angiogenesis Research Group (2003). Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*, *24*(4), 199-202. https://doi.org/10.1159/000074430
- Åsberg A, Mikkelsen G (2024). A bivariate reference interval for TSH and free thyroxine. *Scandinavian journal of clinical and laboratory investigation*, *84*(7-8), 521-526. https://doi.org/10.1080/00365513.2024.2437613
- Guo W, Zhou Q, Jia Y, Xu J (2019). Age- and Sex-Specific Reference Intervals for Myocardial Enzyme Activity in Healthy Chinese Han Population Aged 1∼<18 years. *BioMed research international*, *2019*, 2018598. https://doi.org/10.1155/2019/2018598
- Nalla SD, Chopra S, Rama S, Lambroussis CG (2025). Intravascular Hemolysis and Acute Kidney Injury Following an Emergent Cesarean Delivery: A Case Report. *Cureus*, *17*(8), e90331. https://doi.org/10.7759/cureus.90331
- Trapé J, Montesinos J, Franquesa J, Sala M, Fígols C, Miguel A, Domenech M (2011). Determination of the biological variation of S100β and lactate dehydrogenase in disease-free patients with malignant melanoma. *Clinical chemistry and laboratory medicine*, *50*(5), 927-9. https://doi.org/10.1515/CCLM.2012.799
- Cita KC, Brureau L, Lemonne N, Billaud M, Connes P, Ferdinand S, Tressières B, Tarer V, Etienne-Julan M, Blanchet P, Elion J, Romana M (2016). Men with Sickle Cell Anemia and Priapism Exhibit Increased Hemolytic Rate, Decreased Red Blood Cell Deformability and Increased Red Blood Cell Aggregate Strength. *PloS one*, *11*(5), e0154866. https://doi.org/10.1371/journal.pone.0154866
- Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, ESC Scientific Document Group (2019). Fourth universal definition of myocardial infarction (2018). *European heart journal*, *40*(3), 237-269. https://doi.org/10.1093/eurheartj/ehy462
- Hu J, Zhou S, Ryu S, Adams K, Gao Z (2023). Effects of Long-Term Endurance Exercise on Cardiac Morphology, Function, and Injury Indicators among Amateur Marathon Runners. *International journal of environmental research and public health*, *20*(3). https://doi.org/10.3390/ijerph20032600
- Wu W, Miao L, Zhao L, Zhu Y, Mao J, Cai Z, Ji Y, Wang L, Wang Y, Jia T (2024). Prognostic value of lactate dehydrogenase, serum albumin and the lactate dehydrogenase/albumin ratio in patients with diffuse large B-cell lymphoma. *Hematology (Amsterdam, Netherlands)*, *29*(1), 2293514. https://doi.org/10.1080/16078454.2023.2293514
- Mu T, Wang X, Lu Z, Tong J (2023). Implications of LDH in patients with coronavirus disease 2019 pneumonia. *Frontiers in cellular and infection microbiology*, *13*, 1180187. https://doi.org/10.3389/fcimb.2023.1180187
- Nussinovitch M, Finkelstein Y, Elishkevitz KP, Volovitz B, Harel D, Klinger G, Razon Y, Nussinovitch U, Nussinovitch N (2009). Cerebrospinal fluid lactate dehydrogenase isoenzymes in children with bacterial and aseptic meningitis. *Translational research : the journal of laboratory and clinical medicine*, *154*(4), 214-8. https://doi.org/10.1016/j.trsl.2009.06.011
- Smajić J, Halilović FI, Mujkić L, Sijerčić S, Smajić E, Delibegović S (2026). The clinical relevance of the COVID-19-associated hyperinflammatory syndrome score in the ICU: A single-center retrospective observational study. *Science progress*, *109*(1), 368504261421431. https://doi.org/10.1177/00368504261421431
- Monroe GR, van Eerde AM, Tessadori F, Duran KJ, Savelberg SMC, van Alfen JC, Terhal PA, van der Crabben SN, Lichtenbelt KD, Fuchs SA, Gerrits J, van Roosmalen MJ, van Gassen KL, van Aalderen M, Koot BG, Oostendorp M, Duran M, Visser G, de Koning TJ, ... Jans JJ (2019). Identification of human D lactate dehydrogenase deficiency. *Nature communications*, *10*(1), 1477. https://doi.org/10.1038/s41467-019-09458-6
- Kaviani M, Abassi A, Chilibeck PD (2019). Creatine monohydrate supplementation during eight weeks of progressive resistance training increases strength in as little as two weeks without reducing markers of muscle damage. *The Journal of sports medicine and physical fitness*, *59*(4), 608-612. https://doi.org/10.23736/S0022-4707.18.08406-2
- Huang Y, Long L, Huang Q, Wang Q, Jin K, Ju T, Dai L, Xu H, Wang W, Zhou Q (2024). [Observation on the efficacy of continuous veno-venous hemodia-filtration combined with hemoperfusion HA380 in the treatment of 15 cases of heat stroke with multiple organ dysfunction syndrome]. *Zhonghua wei zhong bing ji jiu yi xue*, *36*(5), 532-537. https://doi.org/10.3760/cma.j.cn121430-20230728-00561
- Jin F, Yang M, Chen Y, Jiang L, Liu L (2020). Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report. *Medicine*, *99*(45), e22632. https://doi.org/10.1097/MD.0000000000022632
- Ansari Z, Findakly D, Wang J (2020). A Retrospective Review of Tumor Lysis Syndrome Associated With Colorectal Cancer. *Cureus*, *12*(5), e8257. https://doi.org/10.7759/cureus.8257
- Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GBJ, Moriarty PM, Morris PB, Muntner P, Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD (2017). Optimizing Cholesterol Treatment in Patients With Muscle Complaints. *Journal of the American College of Cardiology*, *70*(10), 1290-1301. https://doi.org/10.1016/j.jacc.2017.07.752
- Sándor Z, Katics D, Varga, Á., Kalmár Nagy K, Szakály P (2024). Interpretation of LDH Values after Kidney Transplantation. *Journal of clinical medicine*, *13*(2). https://doi.org/10.3390/jcm13020485
- Takagi Y, Yasuhara T, Gomi K (2001). [Creatine kinase and its isozymes]. *Rinsho byori. The Japanese journal of clinical pathology*, *Suppl 116*, 52-61. https://pubmed.ncbi.nlm.nih.gov/11797380/
- Alende-Castro V, Alonso-Sampedro M, Fernández-Merino C, Sánchez-Castro J, Sopeña B, Gude F, Gonzalez-Quintela A (2021). C-Reactive Protein versus Erythrocyte Sedimentation Rate: Implications Among Patients with No Known Inflammatory Conditions. *Journal of the American Board of Family Medicine : JABFM*, *34*(5), 974-983. https://doi.org/10.3122/jabfm.2021.05.210072















